Pharmaceutical US pharma major Bristol-Myers Squibb's (NYSE: BMY) nivolumab will overtake proven blockbuster competitors to dominate the non-small cell lung cancer (NSCLC) treatment market following an expected 2015 launch, says research and consulting firm GlobalData, according to whose latest analysis, nivolumab, a first-in-class immunotherapy, will become the overall NSCLC market sales leader by 2022, reaching revenue of $1.75 billion. 8 July 2013